RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) & GH Research (NASDAQ:GHRS) Critical Review

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares RegeneRx Biopharmaceuticals and GH Research’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RegeneRx Biopharmaceuticals	N/A	N/A	N/A
GH Research	N/A	-15.48%	-15.01%

Valuation & Earnings

This table compares RegeneRx Biopharmaceuticals and GH Research’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RegeneRx Biopharmaceuticals	$80,000.00	0.03	-$1.73 million	N/A	N/A
GH Research	N/A	N/A	-$35.59 million	($0.68)	-16.62

RegeneRx Biopharmaceuticals has higher revenue and earnings than GH Research.

Volatility & Risk

RegeneRx Biopharmaceuticals has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Insider & Institutional Ownership

56.9% of GH Research shares are held by institutional investors. 12.6% of RegeneRx Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for RegeneRx Biopharmaceuticals and GH Research, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RegeneRx Biopharmaceuticals	0	0	0	0	N/A
GH Research	0	0	2	0	3.00

GH Research has a consensus target price of $39.50, suggesting a potential upside of 249.56%. Given GH Research’s higher possible upside, analysts clearly believe GH Research is more favorable than RegeneRx Biopharmaceuticals.

Summary

RegeneRx Biopharmaceuticals beats GH Research on 6 of the 9 factors compared between the two stocks.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.